Cargando…
SARS-CoV-2 vaccine development
SARS-CoV-2 is a well-known viral strain that causes COVID-19. The disease became a pandemic in early 2020 and infected millions of people and killed hundreds of thousands of people worldwide. Vaccine development against the disease was accelerated with multiple collaborations among research institut...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217717/ http://dx.doi.org/10.1016/B978-0-323-85156-5.00046-8 |
_version_ | 1784731714053996544 |
---|---|
author | Mtewa, Andrew G. Amanjot, Annu Lampiao, Fanuel Okella, Hedmon Weisheit, Anke Tolo, Casim U. Ogwang, Patrick |
author_facet | Mtewa, Andrew G. Amanjot, Annu Lampiao, Fanuel Okella, Hedmon Weisheit, Anke Tolo, Casim U. Ogwang, Patrick |
author_sort | Mtewa, Andrew G. |
collection | PubMed |
description | SARS-CoV-2 is a well-known viral strain that causes COVID-19. The disease became a pandemic in early 2020 and infected millions of people and killed hundreds of thousands of people worldwide. Vaccine development against the disease was accelerated with multiple collaborations among research institutions in order to shorten the duration that vaccine development normally takes. Prior coronavirus vaccines present a basis on which vaccines against the current strain can be developed with much speed and relative ease. Among the patented coronavirus vaccines, DNA-based vaccine had the most patents registered which must have clues to guide the efforts in the current works. This work presents some progress on COVID-19 vaccine development and also possible animal venom protein sources that can potentially be used in the pipeline. The future of COVID-19 vaccine is bright with the heightened collaborative efforts and data sharing opportunities that the pandemic has brought among researchers. |
format | Online Article Text |
id | pubmed-9217717 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
record_format | MEDLINE/PubMed |
spelling | pubmed-92177172022-06-23 SARS-CoV-2 vaccine development Mtewa, Andrew G. Amanjot, Annu Lampiao, Fanuel Okella, Hedmon Weisheit, Anke Tolo, Casim U. Ogwang, Patrick Coronavirus Drug Discovery Article SARS-CoV-2 is a well-known viral strain that causes COVID-19. The disease became a pandemic in early 2020 and infected millions of people and killed hundreds of thousands of people worldwide. Vaccine development against the disease was accelerated with multiple collaborations among research institutions in order to shorten the duration that vaccine development normally takes. Prior coronavirus vaccines present a basis on which vaccines against the current strain can be developed with much speed and relative ease. Among the patented coronavirus vaccines, DNA-based vaccine had the most patents registered which must have clues to guide the efforts in the current works. This work presents some progress on COVID-19 vaccine development and also possible animal venom protein sources that can potentially be used in the pipeline. The future of COVID-19 vaccine is bright with the heightened collaborative efforts and data sharing opportunities that the pandemic has brought among researchers. 2022 2022-06-10 /pmc/articles/PMC9217717/ http://dx.doi.org/10.1016/B978-0-323-85156-5.00046-8 Text en Copyright © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Mtewa, Andrew G. Amanjot, Annu Lampiao, Fanuel Okella, Hedmon Weisheit, Anke Tolo, Casim U. Ogwang, Patrick SARS-CoV-2 vaccine development |
title | SARS-CoV-2 vaccine development |
title_full | SARS-CoV-2 vaccine development |
title_fullStr | SARS-CoV-2 vaccine development |
title_full_unstemmed | SARS-CoV-2 vaccine development |
title_short | SARS-CoV-2 vaccine development |
title_sort | sars-cov-2 vaccine development |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217717/ http://dx.doi.org/10.1016/B978-0-323-85156-5.00046-8 |
work_keys_str_mv | AT mtewaandrewg sarscov2vaccinedevelopment AT amanjotannu sarscov2vaccinedevelopment AT lampiaofanuel sarscov2vaccinedevelopment AT okellahedmon sarscov2vaccinedevelopment AT weisheitanke sarscov2vaccinedevelopment AT tolocasimu sarscov2vaccinedevelopment AT ogwangpatrick sarscov2vaccinedevelopment |